Alphatec Holdings (NASDAQ:ATEC) has announced it has launched the IdentiTi Large Window Porous Titanium Interbody Implant System to use in anterior lumbar interbody fusion (ALIF) procedures. As quoted in the press release: “The spine market’s new organic innovation machine continues to deliver meaningful clinical distinction,” said Pat Miles, Chairman and Chief Executive Officer.  “With this fifth of …

Alphatec Holdings (NASDAQ:ATEC) has announced it has launched the IdentiTi Large Window Porous Titanium Interbody Implant System to use in anterior lumbar interbody fusion (ALIF) procedures.

As quoted in the press release:

“The spine market’s new organic innovation machine continues to deliver meaningful clinical distinction,” said Pat Miles, Chairman and Chief Executive Officer. “With this fifth of twelve new product releases expected for 2019, ATEC is on track to fulfill its aggressive new product development and commercialization program. The innovation we are introducing is increasingly being adopted by discriminating spine surgeons.”

ALIF IdentiTi-LW Porous Titanium Interbody Implant System

The launch of the IdentiTi Interbody Implant System follows successful alpha evaluations that began in December 2018. It marks the fourth of six IdentiTi implant systems the Company expects to commercially introduce in 2019.

The IdentiTi line of implant systems is manufactured using a subtractive process, which begets more predictable performance, consistent bone-like porosity, and enhanced imaging characteristics. IdentiTi implants not only complement the Company’s current suite of PEEK implants, but also allow ATEC to address the broader market of surgeons who prefer titanium.

Click here to read the full press release.

Featured
Medtronic Canada ULC, a subsidiary of Medtronic plc the world's leading medical technology company, announced it has received a Health Canada licence for the Hugo™ robotic-assisted surgery system for use in use in urologic and gynecologic laparoscopic surgical procedures, which make up about half of all robotic procedures performed today. 1 "This licence ushers in a new opportunity for healthcare in Canada ...

Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT), the world's leading medical technology company, announced it has received a Health Canada licence for the Hugo™ robotic-assisted surgery (RAS) system for use in use in urologic and gynecologic laparoscopic surgical procedures, which make up about half of all robotic procedures performed today. 1

read more Show less
Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced JUBLIA ® Topical Solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, has received the American Podiatric Medical Association Seal of Approval. The APMA Seal of Approval is granted to products that promote good foot health ...

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced JUBLIA ® (efinaconazole) Topical Solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, has received the American Podiatric Medical Association (APMA) Seal of Approval. The APMA Seal of Approval is granted to products that promote good foot health and are of significant value when used in a consistently applied program of daily foot care and regular professional treatment.

read more Show less
Johnson & Johnson today announced preliminary results from an independent study, including a subset of participants from the Janssen-sponsored COV2008 study, conducted by Dan Barouch M.D., Ph.D., et al. of Beth Israel Deaconess Medical Center which showed that a booster shot of the Johnson & Johnson COVID-19 vaccine administered at six months after a two-dose primary regimen of BNT162b2, increased both antibody and ...

- Johnson & Johnson (NYSE: JNJ) (the Company) today announced preliminary results from an independent study, including a subset of participants from the Janssen-sponsored COV2008 study, conducted by Dan Barouch M.D., Ph.D., et al. of Beth Israel Deaconess Medical Center (BIDMC), which showed that a booster shot of the Johnson & Johnson COVID-19 vaccine (Ad26.COV2.S), administered at six months after a two-dose primary regimen of BNT162b2, increased both antibody and T-cell responses. These results demonstrate the potential benefits of heterologous boosting (mix-and-match). The article describing these results have been posted on medRxiv .

"There is early evidence to suggest that a mix-and-match boosting approach may provide individuals with different immune responses against COVID-19 than a homologous boosting approach," said Dan Barouch , M.D., Ph.D., Director of the Center for Virology and Vaccine Research at BIDMC. "In this preliminary study, when a booster dose of Ad26.COV2.S was given to individuals six months after a primary regimen with the BNT162b2 vaccine, there was a comparable increase of antibody responses at week four following the boost and a greater increase of CD8+ T-cell responses with Ad26.COV2.S compared with BNT162b2."

read more Show less

MARKETS

Markets
TSX21162.65+301.55
TSXV920.55+22.85
DOW35719.43+492.40
S&P 5004686.75+95.08
NASD15686.92+461.76
ASX7313.90+68.80

COMMODITIES

Commodities
Gold1787.77+3.15
Silver22.45-0.06
Copper4.340.00
Palladium1859.78+15.80
Platinum964.50+8.50
Oil71.78-0.27
Heating Oil2.24+0.01
Natural Gas3.83+0.13